ClinicalTrials.gg
RecruitingNCT06706765Updated Nov 27, 2024

Group Telehealth Behavioral Cough Suppression Therapy

An Early Phase 1 interventional study of Behavioral Treatment in Refractory Chronic Cough, sponsored by University of Montana. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-27.

Sponsored by University of Montana · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 9 months ago, but the record still lists the study as recruiting.
  • Registered 5 months after the study started (first participant enrolled Mar 2024, registered Aug 2024).
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Chronic Cough with a site in United States — 9 open to participants now, 10 under way, none of them phase 3. Chronic Cough · United States.

Planned enrollment
15th of 37
60 · median 50
Started
2024
with 2 others
Phase 1
6 of 44
2 open now
Registered
40th of 44
by date
Lead sponsor
5 of 44
University of Montana

Among the 44 studies in Chronic Cough with a site in United States, this one is the 15th largest by planned enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2024, is one of 6 in phase 1, and was the 40th registered.

Chronic Cough

142 studies on the registry are indexed under Chronic Cough; 38 are open to participants now.

Browse Chronic Cough studies →

Open to participants now

9 of the 44 studies in Chronic Cough with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Chronic Cough studies recruiting now, 10 (33%) set no upper age limit and 12 (40%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Chronic Cough with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the effectiveness of behavioral cough suppression therapy (BCST) in managing refractory chronic cough (RCC) within a group telehealth setting. RCC is a cough that has lasted at least 8 weeks and has not resolved with standard medical treatment. BCST is a research-based treatment provided by specialty-trained speech-language pathologists (SLPs) for patients with RCC. Although the treatment works very well for a large proportion of patients in a standard one-on-one format, there are a limited number of SLPs available to provide this treatment and patients living in rural areas do not typically have access to an SLP trained in BCST. If BCST can effectively be delivered in a group telehealth model, it would significantly improve accessibility to the treatment.

03

Conditions studied

  • Refractory Chronic Cough

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years old
  • Predominantly dry cough for at least 8 weeks
  • Evaluated and treated by at least one physician for cough
  • Obtained a chest X-ray or chest CT scan specifically related to the cough with unremarkable results
  • Access to a computer or tablet that includes a camera and able to use the device independently
  • Reliable internet access
  • Willing to agree to maintain confidentiality of personal information (including names) related to others in the study

Exclusion criteria

Exclusion Criteria:

  • Under age 18
  • Coughing up blood
  • Current smoker of any substance
  • History of smoking or 10 or more years
  • Diagnosed with a chronic lung condition (e.g., , emphysema, lung cancer, idiopathic pulmonary fibrosis, chronic bronchitis, asthma)? (NOTE: If a patient has been told their cough may be (or is likely) due to asthma but they have not had any formal lung testing and asthma treatments have not helped your cough, we don't consider this a formal asthma diagnosis and will not exclude them from the study.)
  • Diagnosed currently or in the past with head and neck cancer (i.e., cancer of the mouth, nose, or throat).
  • Complaints of swallowing difficulty
  • Taking any of the following medications, which have a known side effect of cough: Benzapril (Lotensin), Captopril (Capoten), Enalapril/Enalaprilat (Vasotec oral and injectable), Fosinopril (Monopril), Lisinopril (Zestril and Prinivil), Moexipril (Univasc), Perindopril (Aceon), Quinapril (Accupril), Ramipril (Altace), and Trandolapril (Mavik)
  • Prior BCST treatment with an SLP or respiratory therapist
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Group Telehealth Behavioral Cough Suppression Therapy

    Behavioral: Behavioral Treatment

Interventions

  • BehavioralBehavioral Treatment

    Behavioral cough suppression therapy delivered in a group setting via telehealth.

06

What researchers measure

Primary outcomes

  1. Leicester Cough Questionnaire

    The Leicester Cough Questionnaire is a 19-item self-report questionnaire that is valid and reliable, and repeatable every two weeks. The total possible score is 21. The higher the score the better the cough-related quality of life.

    Time frame: Baseline, one-week post-treatment, and one-month post-treatment

Secondary outcomes

  1. Patient Global Impression of Severity Scale in Chronic Cough

    The Patient Global Impression of Severity Scale in Chronic Cough involves the patient answering the question "how do you rate your overall current cough severity?" with options of "no problem, mild, moderate, or severe problem."

    Time frame: Baseline, every treatment session (4-6 treatment sessions, one treatment session per week), and one-month post-treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2024 (actual). Primary completion is estimated for Jan 2025, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2024
First posted
Nov 27, 2024
StartActual
Mar 22, 2024
Primary completionEst.
Jan 31, 2025
CompletionEst.
Jan 31, 2025
Last update
Nov 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06706765
Lead sponsor
University of Montana
Responsible party
Sponsor
First posted
Nov 27, 2024
Start date
Mar 22, 2024
Primary completion
Jan 31, 2025 (estimated)
Completion
Jan 31, 2025 (estimated)
Last update
Nov 27, 2024

Study contacts

Jane E Reynolds, PhD
Contact
jane.reynolds@mso.umt.edu
406-243-2138
Laurie J Slovarp, PhD
Contact
laurie.slovarp@mso.umt.edu
406-243-2107

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion